Nalaganje...
The BCR-ABL(35INS) insertion/truncation mutant is kinase-inactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia
Chronic myeloid leukemia is effectively treated with imatinib, but reactivation of BCR-ABL frequently occurs through acquisition of kinase domain mutations. The additional approved ABL tyrosine kinase inhibitors (TKIs) nilotinib and dasatinib, along with investigational TKIs such as ponatinib (AP245...
Shranjeno v:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
American Society of Hematology
2011
|
| Teme: | |
| Online dostop: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3217407/ https://ncbi.nlm.nih.gov/pubmed/21908430 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-05-349191 |
| Oznake: |
Označite
Brez oznak, prvi označite!
|